Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma

Cereblon (CRBN) is essential for the anti-myeloma (MM) activity of immunomodulatory drugs (IMiDs), such as thalidomide and lenalidomide. However, the clinical implications of CRBN in MM patients are unclear. Using immunohistochemical (IHC) staining on paraffin-embedded bone marrow sections, the expr...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shang-Yi, Lin, Chung-Wu, Lin, Hsiu-Hsia, Yao, Ming, Tang, Jih-Luh, Wu, Shang-Ju, Chen, Yao-Chang, Lu, Hsiao-Yun, Hou, Hsin-An, Chen, Chien-Yuan, Chou, Wen-Chien, Tsay, Woei, Chou, Sheng-Je, Tien, Hwei-Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082140/
https://www.ncbi.nlm.nih.gov/pubmed/24687382
http://dx.doi.org/10.1007/s00277-014-2063-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082140/
https://www.ncbi.nlm.nih.gov/pubmed/24687382
http://dx.doi.org/10.1007/s00277-014-2063-7

Ejemplares similares